Medtronic said it will pay $22 million to settle about 1,000 legal claims related to its spine surgery product known as Infuse, and it is setting aside up to $140 million for an even larger number of expected claims.
The payment announced Tuesday is the latest chapter in a medical saga played out over more than a decade that became a symbol of how conflicts of interest in medicine can adversely affect the health of patients.
